Bladder Cancer Coverage from Every Angle
Advertisement
Advertisement

DANUBE Trial: Survival Outcomes With Durvalumab in Advanced Urothelial Carcinoma

By: Kayci Reyer
Posted: Sunday, November 1, 2020

According to the results of the phase III DANUBE trial, published in The Lancet Oncology, the PD-L1 inhibitor durvalumab did not result in significant benefit for patients with unresectable, locally advanced or metastatic urothelial carcinoma. In fact, the study did not meet either of its co-primary endpoints. Joaquim Bellmunt, MD, of Harvard Medical School, and colleagues assessed the survival outcomes of durvalumab used as monotherapy as well as in conjunction with the CTLA-4 inhibitor tremelimumab.

The trial included 1,032 patients with untreated, unresectable, locally advanced or metastatic urothelial carcinoma who were randomly assigned to receive durvalumab monotherapy (n = 346), durvalumab plus tremelimumab (n = 342), or standard-of-care chemotherapy (n = 344). Patients were stratified by PD-L1 expression. Overall survival was compared between the subpopulation of patients with high PD-L1 expression in the monotherapy versus chemotherapy groups and between patients in the combination therapy versus the intention-to-treat population.

At a median follow-up of 41.2 months, the median overall survival among patients with high expression of PD-L1 was 14.4 months in the monotherapy group versus 21.1 months in the chemotherapy group. The median overall survival in the combination-therapy group was 15.1 months versus 12.1 months in the chemotherapy group.

Grade 3 or 4 adverse events occurred in the majority of patients (60%; n = 188) receiving chemotherapy, with the most common being neutropenia, and in 47 patients (14%) receiving monotherapy and 93 patients (27%) receiving combination therapy, with both groups most commonly experiencing increased lipase levels. Serious treatment-related adverse events were most common in the combination-therapy group (23%; n = 28), followed by the chemotherapy (16%; n = 50) and monotherapy (9%; n = 30) groups. Overall, five patients—two treated with monotherapy, two treated with combination therapy, and one treated with chemotherapy—died due to study drug toxicity.

Disclosure: For full disclosures of the study authors, visit thelancet.com.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.